Information Provided By: 
Fly News Breaks for July 27, 2017
ABMD
Jul 27, 2017 | 13:24 EDT
Piper Jaffray analyst Matt O'Brien says Abiomed remains his favorite mid-cap name following the company's Q2 results. "Simply put, this story continues to chug along positively," O'Brien tells investors in a research note. He "strongly" encourages investors to start or build positions in the name. The analyst has an Overweight rating on Abiomed and upped his price target for the shares to $160 from $145.
News For ABMD From the Last 2 Days
There are no results for your query ABMD
